Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Often patients reach their goal weight and feel good about themselves. Then, because of the initial success, they decide the ...

There's a warning for people looking to buy Mounjaro and Ozempic online or without a prescription, as many look to obtain the weight loss wonder drugs privately, ahead of the long waits for NHS ...

What are the side effects of Mounjaro? “When starting Mounjaro, you’ll be prescribed a starting dose to begin with to allow your body to adjust to the medication and get used to side effects ...

Looking ahead to 2025 is a team of Evercore ISI strategists led by Julian Emanuel, who in our call of the day, offer up some stocks which lost ground in 2024 but which could be see a rebound in ...

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025.

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Mounjaro patients typically start on a 2.5 mg-dose injection once per week for four weeks. This dose is gradually bumped up by an additional 2.5mg every four weeks. The highest dose of Mounjaro ...

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.